SN.L - Smith & Nephew plc

LSE - LSE Delayed price. Currency in GBp

Smith & Nephew plc

Building 5
Croxley Park Hatters Lane
Watford WD18 8YE
United Kingdom
44 1923 477 100
http://www.smith-nephew.com

SectorHealthcare
IndustryMedical Devices
Full-time employees17,637

Key executives

NameTitlePayExercisedYear born
Mr. Roland D. DiggelmannChief Exec. Officer1.49MN/A1967
Ian MellingInterim Chief Financial OfficerN/AN/AN/A
Mr. Mark GladwellPres of Global Operations and Global Bus. ServicesN/AN/A1975
Mr. Andrew SwiftVP of Investor RelationsN/AN/AN/A
Ms. Catheryn O'RourkeChief Legal & Compliance OfficerN/AN/A1973
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Corporate governance

Smith & Nephew plc’s ISS governance QualityScore as of 7 December 2019 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more